AC Immune
Yahoo Finance • 29 days ago
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway Strategic review by executive management yields increased pipeline focus and operational efficiencies with a workforce reduction of around 30%Increased... Full story
Yahoo Finance • 2 months ago
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical developmentACI-7104.056 anti-alpha-syn... Full story
Yahoo Finance • 6 months ago
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein (a-syn) antibody levels on averag... Full story
Yahoo Finance • 6 months ago
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company’s industry-leading pipeline of active immunotherapies for precision prevention... Full story
Yahoo Finance • 7 months ago
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential milestones of up to about $2.1 bil... Full story
Yahoo Finance • 2 years ago
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
AC Immune SA AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company’s strategy is focused on advancing the Phase 2 development of its three active immunotherapies Active immunotherapy now considered to be the optimal app... Full story
Yahoo Finance • 2 years ago
AC Immune to Present at the Jefferies 2023 London Healthcare Conference
AC Immune to Present at the Jefferies 2023 London Healthcare Conference Lausanne, Switzerland, November 7, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative... Full story
Yahoo Finance • 2 years ago
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update Results from amyloid plaque reduction analysis (Abeta-PET) after 6 months of treatment with ACI-24.060 in ABATE Phase 1b/2 study on track for H1 2024AC... Full story
Yahoo Finance • 2 years ago
We're Not Very Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, y... Full story
Yahoo Finance • 2 years ago
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023 Lausanne, Switzerland, November 02, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmac... Full story
Yahoo Finance • 2 years ago
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
PRESSRELEASE AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic ACI-125891 delivers the first element of a precision medicine approac... Full story
Yahoo Finance • 2 years ago
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference Lausanne, Switzerland, October 17, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative d... Full story
Yahoo Finance • 2 years ago
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 Lausanne, Switzerland, October 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenera... Full story
Yahoo Finance • 2 years ago
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
AC Immuneto Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023 Lausanne, Switzerland,September 05,2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision m... Full story
Yahoo Finance • 2 years ago
AC Immune Showcasing Precision Medicine Programs at AAIC 2023
AC ImmuneShowcasingPrecision Medicine Programsat AAIC 2023 Lausanne, Switzerland,July3,2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today anno... Full story
Yahoo Finance • 2 years ago
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
AC ImmuneReceives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy,ACI-24.060, to Treat Alzheimer’s Disease Ongoing Phase 1b/2 ABATE study enrolling well and expanding to sites in USA with Investigational New Drug (IN... Full story
Yahoo Finance • 2 years ago
AC Immune Holds Annual General Meeting of Shareholders
AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by the Board of Directors Lausanne, Switzerland, June 23, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical com... Full story
Yahoo Finance • 3 years ago
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline
AC Immuneat AD/PD™ 2023to PresentNew Clinical and Preclinical Data fromits Precision Medicine Pipeline Ten presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM)AC Immune’s Chief Medical Officer to p... Full story
Yahoo Finance • 3 years ago
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
AC ImmuneReports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein (a-syn) are all on track to reach important mil... Full story
Yahoo Finance • 3 years ago
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
AC Immuneto Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023 Lausanne, Switzerland,March8,2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine f... Full story
